These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 6744328)

  • 1. Prognostic indicators including DNA histogram type, receptor content, and staging related to human breast cancer patient survival.
    Coulson PB; Thornthwaite JT; Woolley TW; Sugarbaker EV; Seckinger D
    Cancer Res; 1984 Sep; 44(9):4187-96. PubMed ID: 6744328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Flow cytophotometry parameters, hormone receptors and axillary lymph node status as prognostic factors in primary breast cancer].
    Kaufmann M; Feichter GE; Nhila A; Klinga K; Abel U
    Geburtshilfe Frauenheilkd; 1988 Oct; 48(10):705-9. PubMed ID: 3234702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Clin Cancer Res; 1998 Jun; 4(6):1489-97. PubMed ID: 9626467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of cellular DNA content on disease-free survival of Stage II breast cancer patients.
    Hedley DW; Rugg CA; Ng AB; Taylor IW
    Cancer Res; 1984 Nov; 44(11):5395-8. PubMed ID: 6488193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiated DNA analysis in relation to steroid receptor status, grading, and staging in human breast cancer.
    Meckenstock G; Bojar H; Hort W
    Anticancer Res; 1987; 7(4B):749-54. PubMed ID: 3674762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex steroid receptors, S-phase fraction and DNA ploidy as determinants of the risk of relapse and death of female breast cancer.
    Lipponen P; Eskelinen M; Papinaho S; Klemi PJ; Aaltomaa S; Kosma VM; Marin S; Syrjänen K
    Anticancer Res; 1992; 12(3):677-82. PubMed ID: 1622125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indicators of prognosis in node-negative breast cancer.
    Sigurdsson H; Baldetorp B; Borg A; Dalberg M; Fernö M; Killander D; Olsson H
    N Engl J Med; 1990 Apr; 322(15):1045-53. PubMed ID: 2320064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA ploidy and survival in breast cancer patients.
    Cornelisse CJ; van de Velde CJ; Caspers RJ; Moolenaar AJ; Hermans J
    Cytometry; 1987 Mar; 8(2):225-34. PubMed ID: 3582068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of steroid hormone receptor content and flow cytometric DNA ploidy in endometrial carcinoma.
    Grénman SE; Klemi P; Toikkanen S; Irjala K; Laippala P; Vähä-Eskeli K; Mäenpää J; Salmi T
    Ann Chir Gynaecol Suppl; 1994; 208():10-4. PubMed ID: 8092757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry.
    Clark GM; Dressler LG; Owens MA; Pounds G; Oldaker T; McGuire WL
    N Engl J Med; 1989 Mar; 320(10):627-33. PubMed ID: 2918874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Breast cancer: prognostic value of flow cytometry and hormone receptors. Apropos of a Lebanese series of patients].
    Aftimos G; Trak-Smayra V; Moacdieh-Rehayel L
    J Med Liban; 2000; 48(1):8-17. PubMed ID: 10881437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of steroid receptor, cell kinetics, and clinical status in patients with breast cancer.
    Kute TE; Muss HB; Anderson D; Crumb K; Miller B; Burns D; Dube LA
    Cancer Res; 1981 Sep; 41(9 Pt 1):3524-9. PubMed ID: 7020931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of DNA image cytometry in Libyan breast cancer.
    Ermiah E; Abdalla F; Buhmeida A; Alshrad M; Salem N; Pyrhönen S; Collan Y
    Oncology; 2012; 83(3):165-76. PubMed ID: 22906963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters.
    Rosanelli GP; Steindorfer P; Wirnsberger GH; Klimpfinger M; Ratschek M; Puerstner P; Auner H; Berhold A
    Anticancer Res; 1995; 15(2):581-6. PubMed ID: 7763041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry.
    Stål O; Sullivan S; Sun XF; Wingren S; Nordenskjöld B
    Cytometry; 1994 Jun; 16(2):160-8. PubMed ID: 7924685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ploidy, proliferative activity and estrogen receptor content in human breast cancer.
    Raber MN; Barlogie B; Latreille J; Bedrossian C; Fritsche H; Blumenschein G
    Cytometry; 1982 Jul; 3(1):36-41. PubMed ID: 7117052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoploidy defines patients with poor prognosis in breast cancer.
    Chavez-Uribe E; Cameselle-Teijeiro J; Viñuela JE; Castro-Piñeiro C; Gude F; Forteza J; Puente-Domínguez JL
    Oncol Rep; 2007 May; 17(5):1109-14. PubMed ID: 17390052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flow cytometry vs. Ki67 labelling index in breast cancer: a prospective evaluation of 181 cases.
    Martínez-Arribas F; Núñez MJ; Piqueras V; Lucas AR; Sánchez J; Tejerina A; Schneider J
    Anticancer Res; 2002; 22(1A):295-8. PubMed ID: 12017306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study of DNA content using a flow cytometry method and steroid hormone receptors in breast cancer].
    Zubrikhina GN; Kuz'mina EV; Bassalyk LS; Murav'eva NI
    Vopr Onkol; 1989; 35(10):1179-86. PubMed ID: 2596061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.
    Nola M; Jukić S; Ilić-Forko J; Babić D; Uzarević B; Petrovecki M; Suchanek E; Skrablin S; Dotlić S; Marusić M
    Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.